Coming soon

In addition to the cell lines already available from the catalogue, another existing 240 lines are will be available shortly once they have passed our QC testing programme.  Lines expected to be released shortly include:

  • Parkinson’s Disease research including Lrrk2 mutations, alpha synuclein triplication and sporadic PD
  • Gaucher’s Disease – GBA mutations
  • Alzheimer’s Disease / ALS – C9orf72 mutations
  • Frontotemporal Dementia – Progranulin mutations
  • Control lines with wide ranging genotype data

An additional 200 reprogrammed lines and CRISPR mediated gene edited control lines are being generated by EBiSC consortium partners.  These lines will cover the following areas of biomedical research:

  • Dravet Syndrome
  • Low birth weight / diabetes
  • Cardiomyopathies/arrhythmias
  • Parkinson’s Disease
  • Facioscapulohumeral-muscular dystrophy (FSHD)
  • Alzheimer’s Disease
  • Frontotemporal Dementia (FTD)
  • Motor Neuron Disease / ALS
  • Duchenne Muscular Dystrophy (DMD)
  • Age-related Macular Degeneration (AMD)

More detailed information on these new lines will be made available once the lines have been characterised.

Do not hesitate to contact EBiSC if you have particular interest about these lines.